8-K: Akari Therapeutics Secures $1.615 Million in Private Placement Amidst Merger Plans

Akari Therapeutics has entered into a definitive agreement for a private placement of approximately $1.615 million of American Depository Shares (ADS) with existing investors, concurrent with its proposed merger with Peak Bio, Inc.

Summary

• Akari Therapeutics, Plc has agreed to a private placement with existing investors to sell approximately $1.615 million of unregistered American Depository Shares (ADS).
• The purchase price per ADS will be the lower of $1.57 or 70% of the volume weighted average price of the ADSs over the 15 days following the merger announcement, with a floor price of $1.12.
• The private placement is expected to close around March 21, 2024, subject to customary closing conditions.
• Paulson Investment Company, LLC will receive a 10% cash fee of the aggregate purchase price and warrants to purchase 10% of the total ADSs placed.
• The warrants will have a 5-year term, cashless exercise provisions, and an exercise price of 125% of the offering price per ADS.
• Akari has agreed to file a registration statement on Form S-3 by March 31, 2024, to register the resale of the ADSs.

Sentiment

Score: 6

Explanation: The document indicates a necessary capital raise for the company, which is a positive for the company's operations, but the terms of the raise are not particularly favorable for existing shareholders due to potential dilution and fees.

Positives

• The private placement provides Akari with additional capital.
• The involvement of existing investors suggests confidence in the company's future.
• The registration statement will allow investors to resell their shares, increasing liquidity.

Negatives

• The private placement involves the issuance of new shares, which could dilute existing shareholders.
• The price of the ADSs is subject to a formula that could result in a lower price than the current market price.
• The company is paying a 10% cash fee to Paulson Investment Company, which reduces the net proceeds of the placement.

Risks

• The closing of the private placement is subject to customary closing conditions, which may not be met.
• The price of the ADSs could fall below the floor price of $1.12.
• The merger with Peak Bio is still subject to conditions and may not be completed.
• The company is paying a 10% cash fee to Paulson Investment Company, which reduces the net proceeds of the placement.

Future Outlook

The company intends to use the proceeds from the private placement for working capital purposes. The company is also working towards completing the merger with Peak Bio and registering the resale of the ADSs.

Industry Context

The private placement is a common method for biotech companies to raise capital, especially when pursuing mergers or acquisitions. The terms of the placement, including the warrants and fees, are typical for this type of transaction. The merger with Peak Bio is part of a broader trend of consolidation in the biotech industry.

Comparison to Industry Standards

• The use of a private placement to raise capital is a standard practice in the biotech industry, particularly for companies in Akari's stage of development.
• The 10% cash fee to the placement agent is within the typical range for such transactions.
• The warrant coverage of 10% is also a common incentive for investors in private placements.
• The pricing mechanism, using a discount to the market price with a floor, is a standard approach to attract investors while providing downside protection.
• Comparable companies such as XOMA Corporation and Agenus Inc. have also used private placements to raise capital, often with similar terms and conditions.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares.
• Investors in the private placement will gain a stake in the company.
• The company will have additional capital to fund its operations and merger plans.

Next Steps

• The company will close the private placement around March 21, 2024.
• The company will file a registration statement on Form S-3 by March 31, 2024.
• The company will continue to work towards completing the merger with Peak Bio.

Key Dates

Keywords

private placement, American Depository Shares, ADS, Akari Therapeutics, Peak Bio, merger, capital raise, Paulson Investment Company, registration statement, warrants